To ensure the quality and safety of medical services in primary healthcare institutions, China’s National Health Commission (NHC) and other relevant authorities issued a notice on 1 April 2026, outlining a three-year nationwide action.

Microplate-based automatic blood grouping analyzer Metis of Aikang MedTech Co., Ltd. (henceforth referred to as Aikang) received approval for marketing in 2015; and its MGT-based automatic blood grouping analyzer Aigel received approval for marketing in 2016.

The US Food and Drug Administration's recent proposal to reclassify companion diagnostic assays as Class Il devices may lead to additional opportunities for diagnostic test manufacturers, diagnostic industry stakeholders claim.

Diagnostics firm TrilliumBio said Tuesday that it is collaborating with Oncobit to offer the Swiss company's uveal melanoma monitoring assay in the US.

German diagnostic startup Amplifold said Wednesday that it has raised €5 million ($5.8 million) in an oversubscribed seed financing round.

Roche announced Tuesday that its PCR-based test for vaginitis has received CE marking. The test is now available in countries accepting the designation.

Molecular diagnostics firm BillionToOne reported after the close of the market on Tuesday that its Q3 2025 revenues more than doubled year over year.

Pillar Biosciences and AstraZeneca said Monday that they are expanding their collaboration on liquid biopsy testing to include China.

The Global Health Innovative Technology (GHIT) Fund said Monday that it has invested ¥70 million ($460,000) in the development of a prototype molecular assay to detect mpox.

Against the background of an increasingly aging global population, the incidence of thrombotic and hemostatic diseases, including cardiovascular diseases, remains high.

Paradigm Health announced last Thursday that it acquired Flatiron Health's clinical research business, establishing a multiyear collaboration between the two companies.

Natera announced last Friday that it has acquired cancer diagnostic firm Foresight Diagnostics for $275 million upfront.